ClinicalTrials.gov record
Completed Phase 4 Interventional

Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy

ClinicalTrials.gov ID: NCT02227550

Public ClinicalTrials.gov record NCT02227550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation

Study identification

NCT ID
NCT02227550
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Atrial Fibrillation Network
Other
Enrollment
676 participants

Conditions and interventions

Interventions

  • Apixaban Drug
  • Vitamin K antagonist Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2014
Primary completion
Mar 31, 2017
Completion
Aug 31, 2017
Last update posted
Oct 19, 2017

2014 – 2017

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Montefiore Medical Center New York New York
Hospital of the University of Pennsyvlania Philadelphia Pennsylvania
Vanderbilt University Medical Center Nashville Tennessee
Texas Cardiac Arrhythmia Research Austin Texas
Sentara Cariovascular Research Insititute Norfolk Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02227550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2017 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02227550 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →